These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30565428)

  • 1. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
    Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
    Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression.
    Yan J; Jiang JY; Meng XN; Xiu YL; Zong ZH
    J Exp Clin Cancer Res; 2016 Feb; 35():31. PubMed ID: 26872615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUSD2 promotes cancer metastasis and confers cisplatin resistance in high grade serous ovarian cancer.
    Xu Y; Miao C; Jin C; Qiu C; Li Y; Sun X; Gao M; Lu N; Kong B
    Exp Cell Res; 2018 Feb; 363(2):160-170. PubMed ID: 29305171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
    El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
    Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCK Promotes High-Grade Serous Ovarian Cancer Tumorigenesis through CD44 and NOTCH3 Signaling.
    Khella CA; Franciosa L; Rodirguez-Rodriguez L; Rajkarnikar R; Mythreye K; Gatza ML
    Mol Cancer Res; 2023 Oct; 21(10):1037-1049. PubMed ID: 37342066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.
    Wu AY; Gu LY; Cang W; Cheng MX; Wang WJ; Di W; Huang L; Qiu LH
    J Exp Clin Cancer Res; 2019 Apr; 38(1):176. PubMed ID: 31023317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-488 inhibits ovarian cancer cell metastasis through regulating CCNG1 and p53 expression.
    Guo JY; Wang XQ; Sun LF
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):2902-2910. PubMed ID: 32271408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
    Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
    Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer.
    Wu H; Li R; Zhang Z; Jiang H; Ma H; Yuan C; Sun C; Li Y; Kong B
    J Ovarian Res; 2019 Dec; 12(1):125. PubMed ID: 31884974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
    Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
    J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non‑coding RNA OIP5‑AS1 facilitates the progression of ovarian cancer via the miR‑128‑3p/CCNG1 axis.
    Liu Y; Fu X; Wang X; Liu Y; Song X
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer.
    Shang Y; Feng B; Zhou L; Ren G; Zhang Z; Fan X; Sun Y; Luo G; Liang J; Wu K; Nie Y; Fan D
    Oncotarget; 2016 Jan; 7(1):538-49. PubMed ID: 26623719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.
    Kreuzinger C; von der Decken I; Wolf A; Gamperl M; Koller J; Karacs J; Pfaffinger S; Bartl T; Reinthaller A; Grimm C; Singer CF; Braicu EI; Cunnea P; Gourley C; Smeets D; Boeckx B; Lambrechts D; Perco P; Horvat R; Berns EMJJ; Cacsire Castillo-Tong D
    Cancer Lett; 2019 Sep; 459():1-12. PubMed ID: 31150822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
    Price JC; Azizi E; Naiche LA; Parvani JG; Shukla P; Kim S; Slack-Davis JK; Pe'er D; Kitajewski JK
    PLoS One; 2020; 15(6):e0233962. PubMed ID: 32525899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
    Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
    Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
    Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing.
    Cole AJ; Dwight T; Gill AJ; Dickson KA; Zhu Y; Clarkson A; Gard GB; Maidens J; Valmadre S; Clifton-Bligh R; Marsh DJ
    Sci Rep; 2016 May; 6():26191. PubMed ID: 27189670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 protein aggregation promotes platinum resistance in ovarian cancer.
    Yang-Hartwich Y; Soteras MG; Lin ZP; Holmberg J; Sumi N; Craveiro V; Liang M; Romanoff E; Bingham J; Garofalo F; Alvero A; Mor G
    Oncogene; 2015 Jul; 34(27):3605-16. PubMed ID: 25263447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.